throbber

` CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`APPLICATION NUMBER:
`
`206276Orig1s000
`LABELING
`
`
`
`

`

`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`PAZEO safely and effectively. See full prescribing information
`for PAZEO.
`
`PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7%
`For topical ophthalmic administration.
`Initial U.S. Approval: 1996
`
`-------------------INDICATIONS AND USAGE-----------------
`PAZEO is a mast cell stabilizer indicated for the treatment of ocular
`itching associated with allergic conjunctivitis. (1).
`
`--------------DOSAGE AND ADMINISTRATION-------------
`The recommended dose is one drop in each affected eye once a day. (2)
`
`-------------DOSAGE FORMS AND STRENGTHS------------
`Ophthalmic solution: 7.76 mg of olopatadine hydrochloride in one
`mL of solution (0.7%) in a four mL bottle. (3)
`
`---------------------CONTRAINDICATIONS---------------------
`None.
`
`--------------WARNINGS AND PRECAUTIONS--------------
`Contamination of Tip and Solution. To prevent contaminating the
`dropper tip and solution, do not touch the eyelids or surrounding
`areas with the dropper tip of the bottle. (5.1)
`
`---------------------ADVERSE REACTIONS---------------------
`The most common adverse reactions (2-5%) were blurred vision,
`superficial punctate keratitis, dry eye, abnormal sensation in eye, and
`dysgeusia. (6)
`
`To report SUSPECTED ADVERSE REACTIONS, contact Alcon
`Laboratories, Inc. at 1-800-757-9195 or FDA at
`1-800-FDA-1088 or www fda.gov/medwatch.
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA
`approved patient labeling.
`
`Revised: 1/2015
`___________________________________________________________________________________________________________
`
`11
`12
`
`13
`
`14
`16
`17
`
`DESCRIPTION
`CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`12.3
`Pharmacokinetics
`NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`CLINICAL STUDIES
`HOW SUPPIED/STORAGE AND HANDLING
`PATIENT COUNSELING INFORMATION
`
`*Sections or subsections omitted from the full prescribing
`information are not listed.
`
`INDICATIONS AND USAGE
`DOSAGE AND ADMINISTRATION
`DOSAGE FORMS AND STRENGTHS
`CONTRAINDICATIONS
`WARNINGS AND PRECAUTIONS
`ADVERSE REACTIONS
`USE IN SPECIFIC POPULATIONS
`8.1
`Pregnancy
`8.3
`Nursing Mothers
`8.4
`Pediatric Use
`8.5
`Geriatric Use
`________________________________________________________________________________________________
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`
`1
`2
`3
`4
`5
`6
`8
`
`Reference ID: 3694617
`
`

`

`FULL PRESCRIBING INFORMATION
`
`INDICATIONS AND USAGE
`1
`PAZEO is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
`
`DOSAGE AND ADMINISTRATION
`2
`The recommended dosage of PAZEO is to instill one drop in each affected eye once a day.
`
`DOSAGE FORMS AND STRENGTHS
`3
`Ophthalmic solution: 7.76 mg of olopatadine hydrochloride in one mL solution (0.7%) in a 4
`mL bottle.
`
`CONTRAINDICATIONS
`4
`None.
`
`5 WARNINGS AND PRECAUTIONS
`5.1 Contamination of Tip and Solution
`As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the
`dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed
`when not in use.
`
`5.2 Contact Lens Use
`Patients should not wear a contact lens if their eye is red.
`
`The preservative in PAZEO solution, benzalkonium chloride, may be absorbed by soft contact
`lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to
`wait at least five minutes after instilling PAZEO before they insert their contact lenses.
`
`6 ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`
`Because clinical trials are conducted under widely varying conditions, adverse reaction rates
`observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials
`of another drug and may not reflect the rates observed in practice.
`
`In a randomized, double-masked, vehicle-controlled trial, patients at risk for developing allergic
`conjunctivitis received one drop of either PAZEO (N=330) or vehicle (N=169) in both eyes for 6
`weeks. The mean age of the population was 32 years (range 2 to 74 years). Thirty-five percent
`were male. Fifty-three percent had brown iris color and 23% had blue iris color. The most
`commonly reported adverse reactions occurred in 2-5% of patients treated with either PAZEO or
`vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia and
`abnormal sensation in eye.
`
`USE IN SPECIFIC POPULATIONS
`8
`8.1 Pregnancy
`
`Reference ID: 3694617
`
`

`

`Risk Summary
`There are no adequate or well-controlled studies with PAZEO in pregnant women. Olopatadine
`caused maternal toxicity and embryofetal toxicity in rats at levels 1,080 to 14,400 times the
`maximum recommended human ophthalmic dose (MRHOD). There was no toxicity in rat
`offspring at exposures estimated to be 45 to 150 times that at MRHOD. Olopatadine should be
`used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
`
`Animal Data
`In a rabbit embryofetal study, rabbits treated orally at 400 mg/kg/day during organogenesis
`showed a decrease in live fetuses. This dose is 14,400 times the MRHOD, on a mg/m2 basis.
`
`An oral dose of 600 mg/kg/day olopatadine (10,800 times the MRHOD) was shown to be
`maternally toxic in rats, producing death and reduced maternal body weight gain. When
`administered to rats throughout organogenesis, olopatadine produced cleft palate at 60
`mg/kg/day (1080 times the MRHOD) and decreased embryofetal viability and reduced fetal
`weight in rats at 600 mg/kg/day. When administered to rats during late gestation and throughout
`the lactation period, olopatadine produced decreased neonatal survival at 60 mg/kg/day and
`reduced body weight gain in offspring at 4 mg/kg/day. A dose of 2 mg/kg/day olopatadine
`produced no toxicity in rat offspring. An oral dose of 1 mg/kg olopatadine in rats resulted in a
`range of systemic plasma area under the curve (AUC) levels that were 45 to 150 times higher
`than the observed human exposure [9.7 ng∙hr/mL] following administration of the recommended
`human ophthalmic dose.
`
`8.3 Nursing Mothers
`Olopatadine has been identified in the milk of nursing rats following oral administration. Oral
`administration of olopatadine doses at or above 4 mg/kg/day throughout the lactation period
`produced decreased body weight gain in rat offspring; a dose of 2 mg/kg/day olopatadine
`produced no toxicity. An oral dose of 1 mg/kg olopatadine in rats resulted in a range of systemic
`plasma area under the curve (AUC) levels that were 45 to 150 times higher than the observed
`human exposure [9.7 ng∙hr/mL] following administration of the recommended human
`ophthalmic dose. It is not known whether topical ocular administration could result in sufficient
`systemic absorption to produce detectable quantities in the human breast milk. Nevertheless,
`caution should be exercised when PAZEO is administered to a nursing mother.
`
`8.4 Pediatric Use
`The safety and effectiveness of PAZEO have been established in pediatric patients two years of
`age and older. Use of PAZEO in these pediatric patients is supported by evidence from adequate
`and well-controlled studies of PAZEO in adults and an adequate and well controlled study
`evaluating the safety of PAZEO in pediatric and adult patients.
`
`Geriatric Use
`8.5
`No overall differences in safety and effectiveness have been observed between elderly and
`younger patients.
`
`11 DESCRIPTION
`
`Reference ID: 3694617
`
`

`

`PAZEO is a sterile ophthalmic solution containing olopatadine, which is a mast cell stabilizer,
`for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline,
`water-soluble powder with a molecular weight of 373.88 and a molecular formula of
`C21H23NO3•HCl.
`
`The chemical structure is presented below:
`
`Chemical Name: 11-[(Z)-3(dimethylamino) propylidene]-6-11dihydrodibenz[b,e] oxepin-2-
`acetic acid, hydrochloride
`
`Each mL of PAZEO solution contains an active ingredient [7.76 mg of olopatadine
`hydrochloride ( 7 mg olopatadine)] and the following inactive ingredients: povidone;
`hydroxypropyl-gamma-cyclodextrin; polyethylene glycol 400; hydroxypropyl methylcellulose;
`boric acid; mannitol; benzalkonium chloride 0.015% (preservative); hydrochloric acid/sodium
`hydroxide (to adjust pH); and purified water.
`
`PAZEO solution has a pH of approximately 7.2 and an osmolality of approximately 300
`mOsm/kg.
`
`12 CLINICAL PHARMACOLOGY
`
`12.1 Mechanism of Action
`Olopatadine is a mast cell stabilizer and a histamine H1 antagonist. Decreased chemotaxis and
`inhibition of eosinophil activation has also been demonstrated.
`
`12.3 Pharmacokinetics
`In healthy subjects, topical ocular dosing of 1 drop of PAZEO once daily for 7 days into both
`eyes resulted in mean ± SD (range) steady state plasma olopatadine Cmax and AUC0-12 of 1.6 ±
`0.9 ng/mL (0.6 to 4.5 ng/mL) and 9.7 ± 4.4 ng*h/mL (3.7 to 21.2 ng*h/mL), respectively. The
`olopatadine Cmax and AUC0-12 after the first dose were similar to those measured on day 7 in
`these subjects, suggesting that there was no systemic accumulation of olopatadine after repeated
`topical ocular dosing with PAZEO. The median (range) time to achieve peak olopatadine
`concentrations (Tmax) was 2.0 hours (0.25 to 4 hours). The mean ± SD (range) elimination
`half-life of olopatadine was 3.4 ± 1.2 hours (2 to 8 hours). N-oxide olopatadine (M3) was
`
`Reference ID: 3694617
`
`

`

`detected during the first 4 hours after bilateral topical ocular dosing of PAZEO in approximately
`half of the subjects and in less than 10% of the total plasma samples collected, at concentrations
`not exceeding 0.121 ng/mL on day 1 and 0.174 ng/mL on day 7. None of the plasma samples
`from these subjects had mono-desmethyl olopatadine (M1) concentrations that were above the
`lower limit of quantitation (0.05 ng/mL) of the PK assay.
`
`13 NONCLINICAL TOXICOLOGY
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`Carcinogenicity
`Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500
`mg/kg/day and 200 mg/kg/day, respectively. Based on a 35 μL drop size and a 60 kg person,
`these doses are approximately 4,500 and 3,600 times the MRHOD, on a mg/m2 basis.
`
`Mutagenesis
`No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse
`mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse
`micronucleus test.
`
`Impairment of fertility
`Olopatadine administered at an oral dose of 400 mg/kg/day (approximately 7,200 times the
`MRHOD) produced toxicity in male and female rats, and resulted in a decrease in the fertility
`index and reduced implantation rate. No effects on reproductive function were observed at 50
`mg/kg/day (approximately 900 times the MRHOD).
`
`14 CLINICAL STUDIES
`The efficacy of PAZEO was established in two randomized, double-masked, placebo-controlled,
`conjunctival allergen challenge (CAC) clinical studies in patients with a history of allergic
`conjunctivitis (Studies 1 and 2).
`
`In Study 1, patients were randomized to receive one of the following study treatments: PAZEO,
`PATADAY, or vehicle ophthalmic solutions. In Study 2, patients were randomized to receive
`one of the following study treatments: PAZEO, PATADAY, PATANOL, or vehicle ophthalmic
`solutions.
`
`Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4
`(incapacitating itch) at several time points after CAC administration. Table 1 displays the mean
`ocular itching severity scores after ocular administration of a specific antigen using the CAC
`model in Studies 1 and 2, respectively. A one unit difference compared to vehicle is considered
`a clinically meaningful change in the ocular itching severity score.
`
`PAZEO demonstrated statistically significantly improved relief of ocular itching compared to
`vehicle at 30-34 minutes, 16 hours, and 24 hours after study treatment. PAZEO demonstrated
`statistically significantly improved relief of ocular itching compared to PATADAY at 24 hours
`after study treatment, but not at 30-34 minutes after study treatment.
`
`Reference ID: 3694617
`
`

`

`Table 1. Itching Scores by Treatment Group and Treatment Difference* in Mean Itching
`Time Point
`PAZEO
`PATADAY
`Vehicle
`(Olopatadine, 0.7%)
`(Olopatadine, 0.2%)
`(N = 66)
`(N = 68)
`Mean
`Difference (95% CI)
`0.36
`-0.02
`(-0.31, 0.26)
`-0.08
`(-0.39, 0.22)
`-0.13
`(-0.44, 0.17)
`-0.17
`(-0.44, 0.11)
`-0.24
`(-0.55, 0.07)
`-0.23
`(-0.54, 0.08)
`-0.48
`(-0.76, -0.20)
`-0.42
`(-0.72, -0.12)
`-0.41
`(-0.72, -0.10)
`
`(N = 68)
`Difference (95% CI)
`-1.54
`(-1.82, -1.25)
`-1.53
`(-1.84, -1.22)
`-1.49
`(-1.80, -1.18)
`-1.50
`(-1.77, -1.23)
`-1.48
`(-1.79, -1.16)
`-1.38
`(-1.69, -1.07)
`-1.61
`(-1.88, -1.33)
`-1.51
`(-1.81, -1.21)
`-1.41
`(-1.72, -1.11)
`
`Study 1
`
`Onset
`
`16h
`
` 3 mins
`
` 5 mins
`
` 7 mins
`
` 3 mins
`
` 5 mins
`
` 7 mins
`
` 24h
`
` 3 mins
`
` 5 mins
`
` 7 mins
`
`Mean
`0.39
`
`0.61
`
`0.61
`
`0.87
`
`1.04
`
`0.98
`
`1.41
`
`1.52
`
`1.50
`
`0.53
`
`0.48
`
`0.70
`
`0.79
`
`0.75
`
`0.93
`
`1.10
`
`1.09
`
`Mean
`1.90
`
`2.06
`
`1.97
`
`2.20
`
`2.27
`
`2.13
`
`2.54
`
`2.62
`
`2.50
`
`Study 2
` Onset
`
`24h
`
` 3 mins
`
` 5 mins
`
` 7 mins
`
` 3 mins
`
` 5 mins
`
` 7 mins
`
`(N = 98)
`0.38
`
`0.53
`
`0.65
`
`1.01
`
`1.22
`
`0.47
`
`0.61
`
`0.61
`
`1.33
`
`1.48
`
`(N = 49)
`(N = 99)
`-1.53
`-0.09
`(-1.76, -1.30)
`(-0.28, 0.09)
`-1.46
`-0.08
`(-1.71, -1.22)
`(-0.29, 0.12)
`-1.17
`0.04
`(-1.45, -0.90)
`(-0.18, 0.26)
`-1.29
`-0.31
`(-1.60, -0.97)
`(-0.57, -0.06)
`-1.15
`-0.26
`(-1.46, -0.84)
`(-0.51, -0.01)
`-0.89
`-0.16
`2.14
`1.41
`1.25
`(-1.22, -0.57)
`(-0.42, 0.11)
`* Mean score estimates, treatment differences and corresponding 95% confidence intervals (CIs) were based on analysis of repeated measures
`using a mixed model with itching scores from each eye (left or right) as the dependent variable and fixed effect terms for investigator, treatment,
`eye-type (left or right), time, and treatment-by-time interaction.;
`The ocular itching score range is 0-4, where 0 is none and 4 is incapacitating itch.
`
`1.91
`
`1.99
`
`1.82
`
`2.30
`
`2.37
`
`Reference ID: 3694617
`
`

`

`16 HOW SUPPLIED/STORAGE AND HANDLING
`PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% is supplied in a white, oval, low
`density polyethylene DROP-TAINER* dispenser with a natural low density polyethylene
`dispensing plug and a white polypropylene cap. Tamper evidence is provided with a shrink band
`around the closure and neck area of the package. PAZEO is supplied in a 4 mL bottle that
`contains 2.5 mL of olopatadine hydrochloride ophthalmic solution [7.76 mg of olopatadine
`hydrochloride in one mL of solution (0.7%)]:
`
`NDC 0065-4273-25
`
`Storage: Store at 2°C to 25°C (36°F to 77°F). Keep bottle tightly closed when not in use.
`
`PATIENT COUNSELING INFORMATION
`17
`●Risk of Contamination: Advise patients to not touch dropper tip to eyelids or surrounding
`areas, as this may contaminate the dropper tip and ophthalmic solution.
`
`●Concomitant Use of Contact Lenses: Advise patients not to wear contact lenses if their eyes
`are red. Advise patients that PAZEO should not be used to treat contact lens-related irritation.
`Advise patients to remove contact lenses prior to instillation of PAZEO. The preservative in
`PAZEO solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be
`reinserted 5 minutes following administration of PAZEO.
`
`Patents: 8,791,154
`
`ALCON®
`
`ALCON LABORATORIES, INC.
`Fort Worth, Texas 76134 USA
`© 201X Novartis.
`
`* is a Trademark of Novartis
`
`Reference ID: 3694617
`
`

`

`in......._....
`
`Active: 7.76 mg
`olopatadine hydrochbride
`equivalent to 7 mg
`olopatadine.
`Inactivcs:
`
`‘
`
`Povidone; hvdmxfoOPW-
`gamma~cyc|odcx1rim
`Momma 9W 400;
`hydroxypropyl
`melhylcellulose; boric
`acid; mmnitnl:
`benzalkonium allows
`0.015% (preservatwe'):
`hydrochloric acid / sodium
`hydroxide (to ad'pst pH);
`and puified later.
`
`CEO I 5 Nnmms Each nL contains:
`
`Rx Only
`FDR TOPICAL
`OPHTHALMIC USE Qn
`Usual Dosage: Insull one
`drop m the affected eye
`once daily.
`‘
`STORAGE: Stow a!
`2°-25°c (36°-77°F)
`
`‘ a Trademark o! Pluvnitu'.
`
`Alum Laboram-ies. Inc." I
`aim Scum Freeway
`Fort Wmth Foxes 76134 L'SA
`1'800-757-“95
`anon majimou akon Ivum
`aned In USA
`
`7
`
`00654|2732
`
`901144441115
`
`
`
`Reference ID: 369461 7
`
`

`

`
`
`
`
`Rx Dnly Each mL contains:
`
`
`a1 2°-25°|3
`ficériveifli'flfi mg qiuggtntldine
`-
`+<-
`0:: an as uwa n
`o-
`o
`'
`
`my? mg oiupatattifine
`.
`E hydrochloride ElaalsuarEuEnge'
`
`* a Trademark of Novartls
`=
`'
`
`ALCUH LMUHflTCHIES, IHB.
`i'l' Sflllfllflfl) 0.7%
`Head insert
`Fort Worth. TI i'fi‘lSd USA
`
`
`--
`
`-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 3694617
`Reference ID: 3694617
`
`

`

`
`
`
`
`
`
`
`
`FDR PROFESSIONAL USE -
`
`Ranlv
`Fol! l'm’lflL.
`
`HUT FDR SflLE
`
`
`
`
`
`
`
`
`WHEY-TEN
`
`mm m I“
`5 NM
`
`
`
`
`
`
`
`
`
`Ioiupalame
`hyimlllond
`ophllahk
`swimmer“
`
`Reference ID: 3694617
`Reference ID: 3694617
`
`

`

`0065-4274-2
`
`le Only Each mL contains:
`Active: 7.76 mg otopatadine
`1ydmchtoride equivaient
`In 1" mg olopatadine
`* a Trademark of Nevada's
`ALBDH LABORATORIES, INC.
`
`FurtWOrth.TX 76134 USA wemorasnom.us:-:10ij
`
`smrage: Share
`at 2°-25°C
`[36°-7?°F].
`Usual Dosage
`Head insert
`e 2015 Nwarus
`
`'
`
`SALE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 3694617
`Reference ID: 3694617
`
`

`

`NDC 0065-4273-27
`
`Pazeofi
`
`(olopatadine a
`hydrod1lofide
`ophthalmic
`
`solution) 0.7%
`
`
`FOR PROFESSIONAL USE
`NOT FOR SALE
`
`
`
`9011599-0115
`
`
`
`
`
`
`
`
`
`0.5 mL Alum-ii
`
`STERILE
`
`* a Trademark of Novartis
`
`Reference ID: 3694617
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`RENATA ALBRECHT
`01/30/2015
`
`Reference ID: 3694617
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket